Company intelligence / Profile preview

SciNeuro Pharmaceuticals

Rockville, Maryland, United Statesscineuro.com ↗

Ownership: Private
Employees: ~28
Development stage: Phase 1

Overview

Completed Phase 1 clinical trial of SNP318 for Alzheimer's disease in November 2023. The trial showed SNP318 was well-tolerated with favorable exposure, strong target engagement, and excellent safety profile. A Phase 2 study is planned for 2024.

Therapeutic areas: Neurology
Modalities: Small moleculesAntisense Oligonucleotides (ASOs)
Industry: Biotech

Drug pipeline

8 assets

snp318

7 more assets in the full pipeline.

Partnerships

GSKSecarna PharmaceuticalsMabylon AG

Beyond the preview

Go deeper on SciNeuro Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SciNeuro Pharmaceuticals.